Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 25M | 211M | 129M | 0 | 0 |
| Gross Profit | 21M | 211M | 129M | 0 | 0 |
| Operating Income | -156M | 47M | -3M | -97M | -51M |
| EBITDA | -142M | 51M | -321K | -95M | -50M |
| Net Income | -144M | 66M | -7M | -95M | -51M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$7.09
+4.11% today
1Y Change
-8.24%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Entrada Therapeutics, Inc. (TRDA) is a Healthcare stock with a market cap of $560.00M and listed on NASDAQ. The stock last traded around $7.09 and down 8.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -87.9%, EPS growth of -297.2%, a dividend yield of 0.0%. What stands out right now is revenue -87.9%, EPS -297.2%, free cash flow -189.7% with operating margin -621.1% and ROIC -44.2%. Valuation already assumes a fairly strong business story at price/sales 22.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TRDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRDA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRDA Max Drawdown
-64.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRDA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$51.2M
+45.9% YoY
Free Cash Flow
-$55.4M
+42.6% YoY
Revenue Growth
-87.9%
EPS Growth
-297.2%
Gross Margin
-54.4%
Net Margin
-565.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 25M | 211M | 129M | 0 | 0 |
| Gross Profit | 21M | 211M | 129M | 0 | 0 |
| Operating Income | -156M | 47M | -3M | -97M | -51M |
| EBITDA | -142M | 51M | -321K | -95M | -50M |
| Net Income | -144M | 66M | -7M | -95M | -51M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90M | 101M | 68M | 45M | 291M |
| Total Assets | 377M | 526M | 469M | 252M | 306M |
| Total Liabilities | 71M | 98M | 227M | 40M | 7M |
| Shareholder Equity | 306M | 429M | 242M | 213M | 299M |
| Total Debt | 51M | 59M | 68M | 26M | 0 |
| Net Debt | -39M | -42M | 628K | -19M | -291M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
51M
+45.8% YoY
Capital Expenditures
5M
-58.6% YoY
Free Cash Flow
55M
+42.6% YoY
Key ratios
Gross Margin
-54.4%
Operating Margin
-621.1%
Net Margin
-565.5%
ROE
-39.8%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.